Interventions for treating COVID-19 in people with chronic kidney disease

Area of Science:

• Nephrology
• Infectious Diseases
• Pharmacology

Background:

• Chronic kidney disease (CKD) affects millions globally, increasing vulnerability to infections.
• Coronavirus disease 2019 (COVID-19) poses significant risks to patients with CKD, including those on dialysis and kidney transplant recipients.
• Evidence-based treatment guidelines for COVID-19 in CKD populations are crucial.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of interventions for treating COVID-19 in individuals with all stages of CKD.
• To synthesize data on benefits and harms of various treatments in CKD patients, encompassing dialysis and transplant recipients.
• To inform clinical practice and future research regarding COVID-19 management in kidney disease.

Main Methods:

• This is a protocol for a Cochrane Review, adhering to rigorous systematic review methodologies.
• The review will include randomized controlled trials and potentially other study designs evaluating interventions for COVID-19 in CKD.
• Data extraction and quality assessment will be performed by multiple independent reviewers.

Main Results:

• The review aims to identify and analyze the benefits and harms of pharmacological and non-pharmacological interventions.
• Specific focus on outcomes such as mortality, hospitalization, viral clearance, and adverse events in the CKD population.
• Results will be stratified by CKD stage, dialysis status, and transplant status where possible.

Conclusions:

• The findings will provide a comprehensive overview of current evidence on COVID-19 treatments for CKD patients.
• This review will highlight gaps in knowledge and identify areas for future research.
• Ultimately, the review seeks to support evidence-based decision-making for clinicians and patients managing COVID-19 in the context of kidney disease.